Bipolar Disorder in Children and Adolescents: Diagnostic and Therapeutic Issues

continued

In addition to ADHD, children with BD have high levels of comorbidity with conduct, anxiety and substance use disorders. Conduct disorder (CD) is a severe condition both from an individual as well as public health perspective, as it represents early antisocial behavior and many of these youngsters come to the attention of the criminal justice system. Various reports have documented an overlap between BD and CD, noting that the comorbid condition heralds a more complicated course. Family genetic work comparing rates of mania and antisocial disorders, as well as the combined condition in relatives of probands stratified by the presence or absence of these disorders, revealed high rates of conduct disorder or antisocial personality disorder (ASPD) in the relatives (Biederman et al., 1997). Further analysis demonstrated the presence of two types of CD/ASPD in the relatives of children with both CD and BD: CD/ASPD with mania ("dysphoric conduct disorder") and CD/ASPD without mania. The issue is clinically an important one: When an irritable and grandiose youngster with mania lies, steals or vandalizes, is it due to the disinhibition of the manic state or is it due to a coexisting antisocial personality? In such cases, if the mania is well-treated, would the conduct problems improve? The answers to these questions, not fully answered, could determine whether such a child should be treated in the mental health care system or enter the criminal justice system.

Juvenile-onset BD may be an important risk factor for substance use disorders (SUD) as well (West et al., 1996; Wilens et al., 2000; Wilens et al., 1999). We have shown that juvenile BD is a risk factor for early cigarette smoking (Wilens et al., 2000) and substance use (Wilens et al., 1999). Of interest, the highest risk for SUD is in individuals with adolescent-onset BD--who have as marked a risk for developing SUD as adolescents with CD (Wilens et al., 1999). It appears that the bulk of SUD in relationship to BD occurs secondary to mania--probably representing some form of self-medication phenomena; however, important family genetic contributions to SUD in this group cannot be ruled out. Of interest, in one controlled study by Geller and associates (1998), lithium (Eskalith, Lithobid) treatment decreased symptoms of both SUD and BD in adolescents, highlighting the importance of a careful clinical history for SUD in BD as well as BD in SUD adolescents--especially those with binge or remarkably excessive patterns of SUD.

Treatment Issues

Few studies are available to guide empirically the treatment of BD in children and adolescents. A small literature has addressed the use of mood-stabilizing medications (valproic acid [Depakote], carbamazepine [Tegretol], lithium carbonate) in this patient population, however, much of this literature is limited by the lack of controlled clinical trials. Lithium, alone and in combination with other medications, is one of the original treatments for bipolar states in youth and continues to be an effective agent, albeit with a number of adverse effects and the need for aggressive monitoring (DeLong, 1978; DeLong and Aldershof, 1987; Kafantaris, 1995).

As part of a multisite study of divalproex sodium, Wagner and colleagues (2002) recently reported improvement in children with BD, replicating work by others (West et al., 1994). Biederman et al. (1998) systemically reviewed the clinical records of all pediatric referral patients with BD and showed that mood stabilizers were associated with significant improvement, albeit relatively slow, of the symptoms of BD. For both lithium and carbamazepine, higher doses and blood levels predicted greater clinical improvement.

More recently, Kowatch et al. (2000), in an open study, showed significant improvement in BD symptoms with divalproex, lithium and carbamazepine. In this study, in which chlorpromazine (Thorazine) rescue was used, approximately 30% to 50% of youth improved. Similarly, Findling (2002) reported on preliminary findings from an ongoing 12-week study of lithium and valproate for youth with BD. Improvements not only in mania, but also in depressive features and overall functioning, were reported with this combination.

The advent of the atypical antipsychotics has provided an alternative treatment for this difficult-to-treat population. In a retrospective chart review study of 28 children and adolescents with BD treated with risperidone (Risperdal), 82% of subjects improved rapidly in manic and aggressive symptoms (Frazier et al., 1999). Furthermore, in an eight-week open study of olanzapine (Zyprexa) monotherapy in 23 children and adolescents, significant improvement was noted in both symptoms of mania and depression on doses ranging from 2.5 mg/day to 20 mg/day (Frazier et al., 2001). Both risperidone and olanzapine were well-tolerated. An interesting study by Delbello and colleagues (2002) showed that combined treatment of adolescents with BD with valproate plus quetiapine (Seroquel) resulted in a better outcome compared to valproate alone. Of note, more subjects in the combined group were reported to be "remitted" from their BD.

While the results associated with these studies of the atypical antipsychotic medications are promising, there is a continued need for additional short- and long-term controlled trials of mood-stabilizing medications of all classes. While well-tolerated, weight gain and the possible risk of tardive dyskinesia limit the utility of the atypical antipsychotic medications.

advertisement

Because childhood-onset BD is a highly comorbid condition, in addition to being treated for BD, most subjects will require a combined pharmacotherapy approach (Wozniak and Biederman, 1996). For instance, when treating BD plus ADHD, studies suggest better outcome and tolerability when treating the BD first and then addressing the ADHD (Biederman et al., 1999). While serotonergic antidepressants are useful in the treatment of depression in BD, careful observation for manic activation is necessary (Biederman et al., 2000). In addition, individuals may require medications for treatment of symptoms of anxiety and obsessive-compulsive disorder that should also be sequenced after the treatment of mania. Because additional medications for ADHD, anxiety and depression may activate mania, these agents must be used cautiously, watching for exacerbation of mood instability.

Acknowledgment and References

Last updated: 04/06

Related Information:

• Toddlers Diagnosed with Bipolar
• Children of Rage and Sorrow - More Children are Battling Mental Illness
• Course of Bipolar Disorder in Youths Described for the First Time
• Bipolar Disorder in Children: How Common Is it?
• About Early-Onset Bipolar Disorder
• How to Help Your Child
• Treatment and Parent’s Role in Treating Your Bipolar Child
• Addressing Educational Needs of Children with Bipolar Disorder
• Living with Bipolar as a Teen: Dealing with School (for teens)
• Mood Swings and Substance Abuse
• Girls with Bipolar Disorder
• Bipolar Patients Show Differences in MRI
• Brain Damage From Bipolar Disorder
• What Causes Bipolar Disorder?
• Bipolar is a Serious Psychiatric Condition
• APA 2004 Mtg. Report: New Research on Biological Psychiatry and Psychopharmacology
• How To Survive Bipolar Disorder
• Family-Focused Therapy Helps Bipolar Patients Cope

back to top ~ bipolar news index ~ send page to a friend